Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $180 to $166.
Read original at benzingaStocks · News reference
Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.39) by 10.07 percent. This is a 45.71 percent decrease over losses of $(1.05) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 11:45 AM
- Checked
- Aug 11, 2026, 11:45 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81
Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.
Read original at benzingaHC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $70 to $65.
Read original at benzinga